Stifel Nicolaus Reaffirms “Buy” Rating for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reissued by equities researchers at Stifel Nicolaus in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $204.00 target price on the stock, up from their prior target price of $178.00. Stifel Nicolaus’ price objective points to a potential upside of 20.18% from the company’s previous close.

Other equities analysts have also recently issued research reports about the company. Citigroup boosted their price objective on Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Guggenheim boosted their price objective on Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Finally, William Blair restated an “outperform” rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $164.22.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $169.75 on Tuesday. Krystal Biotech has a fifty-two week low of $82.09 and a fifty-two week high of $189.97. The stock has a market capitalization of $4.84 billion, a P/E ratio of 2,122.14 and a beta of 0.85. The business has a 50-day moving average of $155.46 and a two-hundred day moving average of $128.83.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.82. The business had revenue of $42.14 million for the quarter, compared to analyst estimates of $27.43 million. During the same period in the prior year, the firm posted ($1.25) EPS. As a group, research analysts expect that Krystal Biotech will post 1.61 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In other news, CAO Kathryn Romano sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $130.00, for a total value of $325,000.00. Following the sale, the chief accounting officer now directly owns 12,556 shares in the company, valued at approximately $1,632,280. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CAO Kathryn Romano sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $130.00, for a total value of $325,000.00. Following the sale, the chief accounting officer now directly owns 12,556 shares in the company, valued at approximately $1,632,280. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the sale, the insider now owns 1,550,882 shares in the company, valued at $265,138,786.72. The disclosure for this sale can be found here. Insiders have sold 40,587 shares of company stock worth $6,535,591 over the last three months. Company insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Large investors have recently bought and sold shares of the business. Los Angeles Capital Management LLC lifted its holdings in Krystal Biotech by 6.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 10,214 shares of the company’s stock worth $1,817,000 after buying an additional 629 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Krystal Biotech by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock worth $302,182,000 after buying an additional 35,632 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Krystal Biotech by 23.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 228,053 shares of the company’s stock worth $28,292,000 after buying an additional 43,709 shares in the last quarter. Eventide Asset Management LLC acquired a new position in Krystal Biotech during the 4th quarter worth $16,932,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Krystal Biotech by 66.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 427,363 shares of the company’s stock worth $53,020,000 after buying an additional 171,157 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).